Antipsychotic polypharmacy (APP) is a controversial topic in the treatment of older adults with schizophrenia. The objective of this study was to examine the use of APP in older adult Asian patients with schizophrenia and its associated demographic and clinical factors.
Methods:
This study was based on the fourth survey of the consortium known as the Research on Asian Psychotropic Prescription Pattern for Antipsychotics. Fifteen Asian countries/territories participated in this survey, including Bangladesh, Mainland China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand, and Vietnam. Basic demographic and clinical characteristics were collected using a standardized data collection form.
Results:
Among the 879 older adults with schizophrenia included in the survey, the rate of APP was 40.5%. Multiple logistic regression analysis revealed that higher antipsychotic doses (P < .001, odds ratio [OR] = 1.003, 95% confidence interval [CI]: 1.002-1.003), longer duration of illness (P = .02, OR = 1.845, 95% CI: 1.087-3.132), and the prescription of anticholinergics (P < .001, OR = 1.871, 95% CI: 1.329-2.635), second-generation antipsychotics (P = .001, OR = 2.264, 95% CI: 1.453-3.529), and first-generation antipsychotics (P < .001, OR = 3.344, 95% CI: 2.307-4.847) were significantly associated with APP.
Conclusion:
Antipsychotic polypharmacy was common in older adult Asian patients with schizophrenia. Compared to the results of previous surveys, the use of APP showed a declining trend over time. Considering the general poor health status of older patients with schizophrenia and their increased risk of drug-induced adverse events, the use of APP in this population needs careful consideration.
KaragianisJNovickDPecenakJ, et al.Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009;63(11):1578–1588.
2.
TiihonenJLonnqvistJWahlbeckK, et al.11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–627.
3.
AuquierPLanconCRouillonFLaderM. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2007;16(12):1308–1312.
4.
FengZLiuCGuanXMorV. China’s rapidly aging population creates policy challenges in shaping a viable long-term care system. Health Aff (Millwood). 2012;31(12):2764–2773.
5.
KohenILesterPELamS. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;6:47–58.
6.
UchidaHMamoDCMulsantBHPollockBGKapurS. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70(3):397–405.
7.
MasandPS. Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(suppl 8):43–49; discussion 50-41.
8.
LehmanAFLiebermanJADixonLB, et al.Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1–56.
9.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1-2):1–30.
10.
NovickDHaroJMHongJ, et al.Regional differences in treatment response and three year course of schizophrenia across the world. J Psychiatr Res. 2012;46(7):856–864.
11.
KreyenbuhlJMarcusSCWestJCWilkJOlfsonM. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv. 2007;58(7):983–990.
12.
FleischhackerWWUchidaH. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17(7):1083–1093.
13.
ItoHKoyamaAHiguchiT. Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005;187:243–247.
14.
HashimotoYUnoJMiwaTKuriharaMTanifujiHTenshoM. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci. 2012;66(5):405–410.
15.
CarnahanRMLundBCPerryPJChrischillesEA. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand. 2006;113(2):135–141.
16.
CentorrinoFGorenJLHennenJSalvatorePKelleherJPBaldessariniRJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700–706.
17.
FisherMDReillyKIsenbergKVillaKF. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. BMC Psychiatry. 2014;14(1):341.
18.
WeinmannSReadJAderholdV. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113(1):1–11.
19.
StahlSMGradyMM. High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv. 2006;57(1):127–129.
20.
ZhuBAscher-SvanumHFariesDECorrellCUKaneJM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008;8:19.
21.
CorrellCURummel-KlugeCCorvesCKaneJMLeuchtS. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–457.
22.
BarbuiCSignorettiAMuleSBosoMCiprianiA. Does the addition of a second antipsychotic drug improve clozapine treatment?Schizophr Bull. 2009;35(2):458–468.
23.
GallegoJABonettiJZhangJKaneJMCorrellCU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28.
24.
UngvariGSChowLYChiuHFNgFSLeungT. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci. 1997;51(5):309–314.
25.
AnFRXiangYTWangCY, et al.Change of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008. Int J Clin Pharmacol Ther. 2010;48(4):270–274.
26.
XiangYTDickersonFKreyenbuhlJ, et al.Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001-2009). J Clin Psychopharmacol. 2012;32(6):809–813.
27.
XiangYTUngvariGSCorrellCUChiuHFShinfukuN. Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiol Psychiatr Sci. 2016;25(1):9–17.
28.
ChongMYTanCHShinfukuN, et al.Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: comparison of REAP-2001 and REAP-2004 studies. Asia-Pacific Psychiatry. 2010;2(2):77–84.
29.
ShinfukuNTanCH. Pharmacotherapy for schizophrenic inpatients in East Asia – changes and challenges. Int Rev Psychiatry. 2008;20(5):460–468.
30.
ColeMGDendukuriN. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry. 2003;160(6):1147–1156.
31.
DassoriAMCopelandLAZeberJEMillerAL. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. Psychiatr Serv. 2011;62(1):47–53.
32.
OlfsonMGerhardTHuangCCrystalSStroupTS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–1181.
33.
LaursenTM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131(1-3):101–104.
34.
WoodsSW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667.
35.
LeuchtSSamaraMHeresS, et al.Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015;41(6):1397–1402.
36.
BarnesTRPatonC. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383–399.
37.
XiangYTBuchananRWUngvariGS, et al.Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. PLoS One. 2013;8(6):e66154.
38.
MorratoEHDoddSOderdaGHaxbyDGAllenRValuckRJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther. 2007;29(1):183–195.
39.
BiancosinoBBarbuiCMarmaiLDonaSGrassiL. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2005;20(6):305–309.
40.
IqbalMMRahmanAHusainZMahmudSZRyanWGFeldmanJM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15(1):33–48.
41.
XiangYTWangCYSiTM, et al.Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust N Z J Psychiatry. 2011;45(11):968–975.
42.
FreudenreichOHendersonDCWalshJPCulhaneMAGoffDC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90–94.
43.
GallegoJANielsenJDe HertMKaneJMCorrellCU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527–542.
44.
ProcyshynRMHonerWGWuTK, et al.Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry. 2010;71(5):566–573.
45.
PhillipsMRLuSHWangRW. Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Am J Psychiatry. 1997;154(9):1228–1234.
46.
KishimotoTWatanabeKUchidaHMimuraMKaneJMCorrellCU. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatry Res. 2013;209(3):406–411.
47.
BrunhamLRChanSLLiR, et al.Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 2014;14(6):555–563.
48.
FoxCRichardsonKMaidmentID, et al.Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–1483.
49.
KurodaNSunSLinCK, et al.Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing. Environ Health Prev Med. 2008;13(5):288–295.
50.
LernerVLibovIKotlerMStrousRD. Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):89–98.
51.
GangulyRKotzanJAMillerLSKennedyKMartinBC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377–1388.
52.
GilmerTPDolderCRFolsomDPMastinWJesteDV. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv. 2007;58(7):1007–1010.
53.
CeylanDAktenerAB AkdedeBAlptekinK. Increase in antipsychotic polypharmacy treatment in patients with schizophrenia between 1994-2000 and 2010. Current Psychopharmacology. 2014;3(2):108–112.
54.
McEvoyJPLiebermanJAStroupTS, et al.Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.
55.
SikichLFrazierJAMcClellanJ, et al.Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420–1431.
56.
BoonlueTSubongkotSDilokthornsakulP, et al.Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand. Clinicoecon Outcomes Res. 2016;8:127.
57.
MirabzadehAKhodaeiMShemshadiH. Antipsychotic polypharmacy versus monotherapy in elderly with chronic schizophrenia: a clinical trial. Eur Psychiatr. 2015;30(suppl 1):1424.
58.
CorrellCUShaikhLGallegoJA, et al.Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131(1-3):58–62.
